Steven K. White;Igor Ivanisevic;Brenton Skylar Wolfe;Mark Andres;Kyle Stephens
发明人:
Steven K. White,Igor Ivanisevic,Kyle Stephens,Mark Andres,Brenton Skylar Wolfe
申请号：
US12418559
公开号：
US08252947B2
申请日:
2009.04.03
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β, 7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β, β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β, 7β,17β-triol and uses of such formulations in treating the described conditions.
